Marburg Virus a Global Infectious Disease: A Review
Abstract
Full Text:
PDFReferences
Martini GA. Marburg virus disease. Postgrad Med J. 1973; 49(574):542-6.
Peterson AT, Holder MT. Datasets: Phylogenetic assessment of filoviruses: how many lineages of Marburg virus. Ecol. Evol. 2012; 2(8): 1826–1833
Brauburger K, Hume AJ, Mühlberger E, et al. Forty-five years of Marburg virus research. Viruses. 2012; 4(10):1878-927.
Falzarano D, Feldmann H. Marburg virus. (2008): 272-280.
Towner JS, Pourrut X, Albariño CG, et al. Marburg virus infection detected in a common African bat. PLoS One. 2007; 2(8): e764. doi: 10.1371/journal.pone.0000764
Paweska JT, Jansen van Vuren P, Fenton KA, et al. Lack of Marburg virus transmission from experimentally infected to susceptible in-contact Egyptian fruit bats. J. Infect. Dis. 2015; 212: S109-18. doi: 10.1093/infdis/jiv132. Epub 2015 Apr 2.
Martini GA, Schmidt HA. Spermatogenic transmission of the" Marburg virus". (Causes of" Marburg simian disease"). Klin Wochenschr. 1968; 46(7):398-400. doi: 10.1007/BF01734141.
https://www.cdc.gov/vhf/marburg/transmission/index.html
Smith CG, Simpson DI, Bowen ET, et al. Fatal human disease from vervet monkeys. Lancet. 1967; 290(7526):1119-21.
Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. Br. Med. J. 1975; 4(5995):489-93.
Conrad JL, Isaacson M, Smith EB, et al. Epidemiologic investigation of Marburg virus disease, Southern Africa, 1975. Am J Trop. Med. Hyg. 1978; 27(6):1210-5.
Smith DH, Isaacson M, Johnson KM, et al. Marburg-virus disease in Kenya. Lancet. 1982; 319(8276):816-20.
Beer B, Kurth R, Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften. 1999; 86(1):8-17.
Bertherat E, Talarmin A, Zeller H. Democratic Republic of the Congo: between civil war and the Marburg virus. International Committee of Technical and Scientific Coordination of the Durba Epidemic. Med. Trop: revue du Corps de sante colonial. 1999; 59(2):201-4.
Hovette P. Epidemic of Marburg hemorrhagic fever in Angola. Med. Trop: revue du Corps de sante colonial. 2005; 65(2):127-8.
Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS. Pathogens. 2009; 5(7). https://doi.org/10.1371/journal.ppat.1000536
Timen A, Koopmans MP, Vossen AC, et al. Response to imported case of Marburg hemorrhagic fever, the Netherlands. Emerg. Infect. Dis. 2009 Aug; 15(8):1171-5. doi: 10.3201/eid1508.090015
Selvaraj SA, Lee KE, Harrell M, et al. Infection rates and risk factors for infection among health workers during Ebola and Marburg virus outbreaks: a systematic review. J. Infect. Dis. 2018; 218: S679-89.
https://www.who.int/csr/don/archive/disease/marburg_virus_disease/en
Ligon BL. Outbreak of Marburg hemorrhagic fever in Angola: a review of the history of the disease and its biological aspects. Semin. Pediatr. Infect. Dis.2005;16: 219-224
Grolla A, Lucht A, Dick D, et al. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull. Soc. Pathol. Exot. 2005; 98(3):205-9.
Grolla A, Jones SM, Fernando L, et al. The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS. Negl. Trop. Dis. 2011;5: e1183. https://dx.doi.org/10.1371%2Fjournal.pntd.0001183
Towner JS, Sealy TK, Ksiazek TG, et al. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J. Infect. Dis. 2007 ; 196: S205-12
Schnittler HJ, Mahner F, Drenckhahn D, et al. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. J. Clin. Investig. 1993; 91(4):1301-9.
Smith DH, Johnson BK, Isaacson M et al. Marburg virus disease in Kenya. Lancet. 1982;1(8276):816-20. doi: 10.1016/s0140-6736(82)91871-2.
Hensley LE, Alves DA, Geisbert JB, et al. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J. Infect. Dis. 2011;204: S1021-31
Shifflett K, Marzi A. Marburg virus pathogenesis–differences and similarities in humans and animal models. Virol. J. 2019; 16(1):1-2.
Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 2015; 212: S91-7.
Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br. J. Exp. Pathol.1968; 49(5):458.
Cross RW, Mire CE, Agans KN, et al. Marburg and Ravn viruses fail to cause disease in the domestic ferret (Mustela putorius furo). J. Infect. Dis.2018; 218: S448-52.
Wong G, Zhang Z, He S, et al. Marburg and Ravn virus infections do not cause observable disease in ferrets. J. Infect. Dis. 2018 Nov 22; 218: S471-4.
Kirchdoerfer RN, Wasserman H, Amarasinghe GK, et al. Filovirus structural biology: the molecules in the machine. Curr. Top. Microbiol. Immunol. 2017; 411:381-417. doi: 10.1007/82_2017_16.
Bhattarai N, Gerstman BS, Stahelin RV, et al. Plasma membrane association facilitates conformational changes in the Marburg virus protein VP40 dimer. RSC. Advances. 2017; 7(37):22741-8.
Olejnik J, Hume AJ, Leung DW, et al. Filovirus strategies to escape antiviral responses. Curr. Top. Microbiol. Immunol. 2017; 411:293-322. doi: 10.1007/82_2017_13.
Zhang AP, Bornholdt ZA, Abelson DM, et al. Crystal structure of Marburg virus VP24. J. Virol. 2014; 88(10):5859-63.
Edwards MR, Johnson B, Mire CE, et al. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell. Reports. 2014; 6(6):1017-25.
Page A, Volchkova VA, Reid SP, et al. Marburgvirus hijacks nrf2-dependent pathway by targeting nrf2-negative regulator keap1. Cell. Reports. 2014; 6(6):1026-36.
Kirchdoerfer RN, Moyer CL, Abelson DM, et al. The Ebola virus VP30-NP interaction is a regulator of viral RNA synthesis. PLoS. Pathogens. 2016; 12(10): e1005937.
Wenigenrath J, Kolesnikova L, Hoenen T, et al. Establishment and application of an infectious virus-like particle system for Marburg virus. J. Gen. Virol. 2010; 91(5):1325-34.
Modrof J, Möritz C, Kolesnikova L, et al. Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions. Virology. 2001; 287(1):171-82.
Yen BC, Basler CF. Effects of filovirus interferon antagonists on responses of human monocyte-derived dendritic cells to RNA virus infection. J. Virol. 2016; 90(10):5108-18.
Guito JC, Albariño CG, Chakrabarti AK, et al. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system. Virology. 2017; 501:147-65.
Koehler A, Pfeiffer S, Kolesnikova L, et al. Analysis of the multifunctionality of Marburg virus VP40. J. Gen. Virol. 2018; 99(12):1614-20.
Kondoh T, Letko M, Munster VJ, et al. Single-nucleotide polymorphisms in human NPC1 influence filovirus entry into cells. J. Infect. Dis. 2018; 218: S397-402.
Gnirß K, Fiedler M, Krämer-Kühl A, et al. Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. Viruses. 2014; 6(4):1654-71.
King LB, West BR, Schendel SL, et al. The structural basis for filovirus neutralization by monoclonal antibodies. Curr. Opin. Immunol. 2018; 53:196-202.
Dolnik O, Stevermann L, Kolesnikova L, et al. Marburg virus inclusions: A virus-induced microcompartment and interface to multivesicular bodies and the late endosomal compartment. Eur. J. Cell. Bio. 2015; 94(7-9):323-31.
Schudt G, Kolesnikova L, Dolnik O, et al. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances. Proc. Nat. Acad. Sci. 2013; 110(35):14402-7.
Mittler E, Schudt G, Halwe S, et al. A fluorescently labeled Marburg virus glycoprotein as a new tool to study viral transport and assembly. J. Infect. Dis. 2018; 218: S318-26.
http://www.who.int/mediacentre/factsheets/fs_marburg/en/
https://www.cdc.gov/vhf/abroad/healthcare-workers.html
Geisbert TW, Hensley LE, Geisbert JB, et al. Postexposure treatment of Marburg virus infection. Emerg. Infect. Dis. 2010; 16(7):1119.
Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 2006; 193(12):1650-7.
Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 2006; 50(3):984-93.
Zhu W, Zhang Z, He S, et al. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral. Res. 2018; 151:39-49.
Ignatyev G, Steinkasserer A, Streltsova M, et al. Experimental study on the possibility of treatment of some hemorrhagic fevers. J. Biotech. 2000; 83(1-2):67-76.
Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. Br. Med. J. 1975; 4(5995):489-93.
Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New. Eng. J. Med. 2001; 344(10):699-709.
Kolokol'tsov AA, Davidovich IA, Strel'tsova MA, et al. The use of interferon for emergency prophylaxis of Marburg hemorrhagic fever in monkeys. Bull. Exp. Biol. Med. 2001; 132(1):686-8.
Thi EP, Mire CE, Ursic-Bedoya R, et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med. 2014; 6(250):250ra116. doi: 10.1126/scitranslmed.3009706
https://www.nih.gov/news-events/news-releases/nih-supported-experimental-marburg-vaccine-prevents-disease-two-days-after-infection
Geisbert TW. Marburg and Ebola Hemorrhagic Fevers (Filoviruses). Mandell, Douglas, and Bennett's Principles and Practice of Infect. Dis. 2015:1995-1999.https://dx.doi.org/10.1016%2FB978-1-4557-4801-3.00166-1
Swenson DL, Warfield KL, Larsen T, et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert. Rev. Vaccines. 2008; 7(4):417-29.
Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26):4071-80.
Ignatyev GM, Agafonov AP, Streltsova MA, et al. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J. Biotech. 1996; 44(1-3):111-8.
Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005; 11(7):786-90.
Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protects guinea pigs and nonhuman primates. Virology. 1998; 251(1):28-37.
Geisbert TW, Bailey M, Geisbert JB, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 2010; 84(19):10386-94.
Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vacc. Immunol. 2008; 15(3):460-7.
Grant-Klein RJ, Altamura LA, Badger CV, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Human. Vacc. Immunotherapeu. 2015; 11(8):1991-2004.
Martini GA. Marburg virus disease. Clinical syndrome. In Marburg virus disease 1971 (pp. 1-9). Springer, Berlin, Heidelberg.
Todorovitch K, Mocitch M, Klašnja R. Clinical picture of two patients infected by the Marburg vervet virus. In Marburg virus disease 1971 (pp. 19-23). Springer, Berlin, Heidelberg.
Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virol. 2003; 314(1):350-7
Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010;16(9):991-4
Ignat'ev GM, Bukin EK, Otrashevskaia EV. An experimental study of possibility of treatment of hemorrhagic fever Marburg by Remicade. Vestn. Ross Akad. Med. Nauk. 2004; (11):22-4.
.
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Research & Reviews: A Journal of Pharmacology